MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Conatus Pharmaceuticals Company Profile (NASDAQ:CNAT)

Consensus Ratings for Conatus Pharmaceuticals (NASDAQ:CNAT) (?)
Ratings Breakdown: 1 Hold Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $10.43 (382.80% upside)

Analysts' Ratings History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Show:
DateFirmActionRatingPrice TargetActions
5/9/2016Brean CapitalReiterated RatingBuy$13.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2016Roth CapitalReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/17/2015JMP SecuritiesLower Price TargetMarket Outperform$10.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2015Stifel NicolausLower Price TargetBuy$11.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/24/2015Piper JaffrayReiterated RatingHold$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/22/2015HC WainwrightInitiated CoverageBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/6/2015MLV & Co.Set Price TargetBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Conatus Pharmaceuticals (NASDAQ:CNAT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/5/2016Q116($0.35)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2016Q4($0.37)($0.30)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.38)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.34)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.38)($0.38)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2015Q414($0.49)($0.34)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q3($0.44)($0.42)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014Q214($0.40)($0.34)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q1($0.33)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/27/2014($0.27)($0.33)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q3($0.20)($0.28)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.44)($0.33)($0.37)
Q2 20163($0.43)($0.35)($0.38)
Q3 20163($0.49)($0.38)($0.42)
Q4 20163($0.45)($0.41)($0.42)
(Data provided by Zacks Investment Research)
Dividend History for Conatus Pharmaceuticals (NASDAQ:CNAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Conatus Pharmaceuticals (NASDAQ:CNAT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/8/2015Daniel L KisnerDirectorBuy4,000$5.75$23,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013David F HaleDirectorBuy2,588$11.00$28,468.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013Luke EvninMajor ShareholderBuy165,265$11.00$1,817,915.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/30/2013Steven J MentoCEOBuy13,800$11.00$151,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Conatus Pharmaceuticals (NASDAQ:CNAT)
DateHeadline
06/28/16 03:17 PMConatus Pharmaceuticals Inc. (NASDAQ:CNAT) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 03:17 PMShare Update and Earnings Review for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Press Telegraph
06/27/16 03:18 PMEquity Research and Technical Review on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Press Telegraph
06/24/16 03:06 PMCONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to -
06/23/16 09:58 AMConatus Pharmaceuticals Inc. (CNAT) Updated Price Targets - FTSE News
06/22/16 08:33 PMStrong Buy Calls Count For Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) At 5 - Investor Newswire
06/22/16 08:33 PMConatus Pharmaceuticals Inc. (CNAT) Current Analyst Ratings - Fiscal Standard
06/20/16 09:36 AMHot Stocks: KeyCorp. (NYSE:KEY), Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), Jazz Pharmaceuticals plc ... - KC Register
06/20/16 09:36 AMConatus Pharmaceuticals Inc. (CNAT) Analyst Price Targets For The Coming Week - Fiscal Standard
06/18/16 07:54 AMCan Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Meet Analysts Expectations? - Stocks Daily
06/14/16 06:49 AMConatus to Present at JMP Securities Life Sciences Conference - [at noodls] - SAN DIEGO, June 14, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its planned participation in the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016, ...
06/01/16 11:48 AMBuy, Sell Or Hold Rating For Conatus Pharmaceuticals Inc. (CNAT)? - Share Trading News - Buy, Sell Or Hold Rating For Conatus Pharmaceuticals Inc. (CNAT)?Share Trading News01/06/2016 – Conatus Pharmaceuticals Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 15 price target on the stock. 11/17/2015 – Conatus Pharmaceuticals Inc. had its “market outperform” rating reiterated by analysts ...and more »
05/31/16 03:22 PMStock Review and Earnings Check on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - HNN - Stock Review and Earnings Check on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)HNNCurrently, sell-side analysts are expecting Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report quarterly EPS of $-0.38. The company's next earnings report is expected to be published on or around 2016-08-03 for the period ending on 2016-06-30.and more »
05/30/16 05:02 PMAfter Last Week What Do Analysts Think Of Conatus Pharmaceuticals Inc. (CNAT) - Share Trading News - After Last Week What Do Analysts Think Of Conatus Pharmaceuticals Inc. (CNAT)Share Trading News03/27/2015 – Conatus Pharmaceuticals Inc. had its “buy” rating reiterated by analysts at MLV & Co. They now have a USD 16 price target on the stock. The share price of Conatus Pharmaceuticals Inc. (CNAT) was down -1.78% during the last trading session, ...Conatus Pharmaceuticals' (CNAT) “Buy” Rating Reiterated at FBR & Co.Let Me Know About Thisall 2 news articles »
05/30/16 08:14 AMTarget Check and Stock Performance Recap Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - HNN - Target Check and Stock Performance Recap Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)HNNIn recent session activity, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares have traded -1.78%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has been ...and more »
05/30/16 08:14 AMConatus Pharmaceuticals Inc. (NASDAQ:CNAT) Daily Sentiment Score Of 0.56 - Investor Newswire - Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Daily Sentiment Score Of 0.56Investor NewswireConatus Pharmaceuticals Inc. (NASDAQ:CNAT) has a daily sentiment score of 0.56. This score is given by Alpha One, which uses its self-designed algorithm to identify market sentiment on the stock after studying the published content on the web. The ...and more »
05/29/16 09:55 PMConatus Pharmaceuticals' (CNAT) “Buy” Rating Reiterated at FBR & Co. - Let Me Know About This - Conatus Pharmaceuticals' (CNAT) “Buy” Rating Reiterated at FBR & Co.Let Me Know About ThisConatus Pharmaceuticals logo Conatus Pharmaceuticals Inc (NASDAQ:CNAT)'s stock had its “buy” rating reiterated by analysts at FBR & Co. in a report issued on Sunday. A number of hedge funds and institutional investors have recently made changes to ...
05/25/16 10:02 PMStock Rating Review for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Wall Street Hints and News - Stock Rating Review for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus ...and more »
05/24/16 10:15 PMEarnings Review and Stock Rundown for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Wall Street Hints and News - Earnings Review and Stock Rundown for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Conatus Pharmaceuticals Inc.and more »
05/23/16 05:03 PMTarget Check and Stock Performance Recap Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - Wall Street Hints and News - Target Check and Stock Performance Recap Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Conatus Pharmaceuticals Inc.and more »
05/23/16 09:51 AMHot Alert: Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), Cleveland BioLabs, Inc. (NASDAQ:CBLI), EPR Properties ... - KC Register - Hot Alert: Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), Cleveland BioLabs, Inc. (NASDAQ:CBLI), EPR Properties ...KC RegisterConatus Pharmaceuticals Inc (NASDAQ:CNAT)'s stock had its “buy” rating restated by analysts at Brean Capital in a research note issued to investors on Monday, Analyst Ratings Network.com reports. They currently have a $7.00 price objective on the ...
05/22/16 09:32 PMConatus Pharmaceuticals Inc. (NASDAQ:CNAT) One-Year Price Target Estimate At $11.17 - Investor Newswire - Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) One-Year Price Target Estimate At $11.17Investor NewswireThe 52-week price target of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) is set at $11.17 after First Call completed its market based survey. It has estimated EPS of $-0.40 for approaching quarter and $-1.55 for ongoing year. The EPS estimate for next ...and more »
05/21/16 04:41 PMConatus Pharmaceuticals Inc. (NASDAQ:CNAT) One-Year Price Projection At $12.2 - RealistInvestor.com - Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) One-Year Price Projection At $12.2RealistInvestor.comSell-side analysts are certain on the prospect of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) stock. As of 2016-05-20, the stock ABR stands at 1. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in such ...and more »
05/17/16 04:52 PMConatus Pharmaceuticals Inc. (NASDAQ:CNAT) Hovering Around $2.230 - Investor Newswire - Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Hovering Around $2.230Investor NewswireOn performing technical analysis of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) stock, it is noted that the stock is $-0.415 points away -15.478% from its fifty-day MA of $2.683. It is $-0.256 or -10.155% away $2.524, the 200-day MA (Moving Average) of ...and more »
05/14/16 12:04 PMCONATUS PHARMACEUTICALS INC. Financials -
05/11/16 03:34 AMConsensus Rating Review for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - B.O.D.Y Confidential - Consensus Rating Review for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/08/16 05:27 PMConatus Pharmaceuticals Inc. (NASDAQ:CNAT) Yearly EPS Target At $-1.48 - Investor Newswire - Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Yearly EPS Target At $-1.48Investor NewswireAs per Thomson Reuters, b>Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) can touch $12.00 in coming 52-weeks. The mean EPS, a year earlier was $-1.34. For the coming quarter, the EPS estimate is $-0.36 while for this fiscal the set target is $-1.48.and more »
05/07/16 04:45 PMConatus Pharmaceuticals Inc. (NASDAQ:CNAT) ABR Of 1 - RealistInvestor.com - Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) ABR Of 1RealistInvestor.comAnalysts have a buy call on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) stock. As of 2016-05-06, it had an ABR of 1. The rating is fixed on a scale of 1-5. Here three stands for hold call. This analyst brokerage rating computation is based on 5 calls.and more »
05/06/16 09:32 AMConatus (CNAT) Posts In Line Q1 Loss , Focus on Emricasan -
05/05/16 10:46 PMConatus Pharmaceuticals (CNAT) Announces Positive Data from Phase 2 Liver Cirrhosis Trial with Emricasan - Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced positive top-line results from the three-month, open-label second stage of the company’s multicenter Phase 2 clinical trial of emricasan, a first-in-class, orally active pan-caspase inhibitor ...
05/05/16 08:30 AMConatus' (CNAT) Q1 Loss in Line with Expectation -
05/05/16 06:40 AMConatus reports 1Q loss -
05/05/16 06:11 AMConatus Pharmaceuticals Reports First Quarter 2016 Financial Results and Program Updates - [at noodls] - SAN DIEGO, May 05, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, ...
05/05/16 06:07 AMQ1 2016 Conatus Pharmaceuticals Inc Earnings Release - Before Market Open -
05/05/16 06:01 AMCONATUS PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financi -
05/04/16 10:26 PMConatus Pharmaceuticals (CNAT) Announces Positive Data from Phase 2 Liver Cirrhosis Trial with Emricasan - StreetInsider.com - Conatus Pharmaceuticals (CNAT) Announces Positive Data from Phase 2 Liver Cirrhosis Trial with EmricasanStreetInsider.comConatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced positive top-line results from the three-month, open-label second stage of the company's multicenter Phase 2 clinical trial of emricasan, a first-in-class, orally active pan-caspase inhibitor, ...and more »
05/04/16 05:17 PMStock Update (NASDAQ:CNAT): Conatus Pharmaceuticals Inc Extends Positive Results with Emricasan in Phase 2 ... - Smarter Analyst - Smarter AnalystStock Update (NASDAQ:CNAT): Conatus Pharmaceuticals Inc Extends Positive Results with Emricasan in Phase 2 ...Smarter AnalystConatus Pharmaceuticals Inc (NASDAQ:CNAT) announced positive top-line results from the three-month, open-label second stage of the company's multicenter Phase 2 clinical trial of emricasan, a first-in-class, orally active pan-caspase inhibitor, in ...and more »
05/04/16 03:31 PMConatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial - [at noodls] - - Continued Directional Improvements in Key Measures of Liver Function after Six Months - - First Drug to Demonstrate Liver Function Benefit in Patients with NASH Cirrhosis - - Conference Call and Webcast ...
05/04/16 10:25 AMDrug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More -
05/04/16 03:35 AMAverage Analyst Rating for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - B.O.D.Y Confidential - Average Analyst Rating for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research ...and more »
05/03/16 05:57 PMConatus (CNAT): Can the Stock Surprise in Q1 Earnings? -
05/01/16 05:54 PMConatus Pharmaceuticals Inc. (NASDAQ:CNAT) Yearly EPS Target At $-1.47 - Investor Newswire - Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Yearly EPS Target At $-1.47Investor NewswireAs per Thomson Reuters, b>Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) can touch $12.67 in coming 52-weeks. The mean EPS, a year earlier was $-1.34. For the coming quarter, the EPS estimate is $-0.36 while for this fiscal the set target is $-1.47.and more »
04/28/16 06:57 AMConatus Pharmaceuticals to Report First Quarter 2016 Financial Results - [at noodls] - SAN DIEGO, April 28, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, ...
04/27/16 04:12 AMConatus Pharmaceuticals Inc. (NASDAQ:CNAT) Share Rating Recap - B.O.D.Y Confidential - Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Share Rating RecapB.O.D.Y ConfidentialShares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly ...and more »
04/26/16 05:47 PMNew Analyst Ratings On Conatus Pharmaceuticals Inc. (CNAT) - Risers & Fallers - New Analyst Ratings On Conatus Pharmaceuticals Inc. (CNAT)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Conatus Pharmaceuticals Inc. (CNAT). The latest broker reports which are currently outstanding on Tuesday 26th of April state 0 analysts have a rating of “strong buy”, ...Conatus Pharmaceuticals Inc. (NASDAQ:CNAT): Will They Hit or Miss with Earnings?Franklin IndependentConatus Pharmaceuticals Inc. (NASDAQ:CNAT) 200-day MA At $2.70Investor Newswireall 3 news articles »
04/24/16 05:54 PMConatus Pharmaceuticals Inc. (CNAT) Broker Price Targets For The Coming Week - Share Trading News - Conatus Pharmaceuticals Inc. (CNAT) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Conatus Pharmaceuticals Inc. (CNAT). The latest reports which are currently in issue on Sunday 24th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
04/21/16 05:37 PMConatus Pharmaceuticals Inc. (NASDAQ:CNAT) Share Rating Recap - The Post - Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Share Rating RecapThe PostShares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly ...and more »
04/20/16 05:32 PMLatest Analyst Ratings For Conatus Pharmaceuticals Inc. (CNAT) - Share Trading News - Latest Analyst Ratings For Conatus Pharmaceuticals Inc. (CNAT)Share Trading News01/06/2016 – Conatus Pharmaceuticals Inc. had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 15 price target on the stock. 11/17/2015 – Conatus Pharmaceuticals Inc. had its “market outperform” rating reiterated by analysts ...
04/19/16 10:50 PMTop Stories: Micron Technology, Inc. (NASDAQ:MU), Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), HollySys ... - KC Register - Top Stories: Micron Technology, Inc. (NASDAQ:MU), Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), HollySys ...KC RegisterConatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that a poster addressing results in both ex vivo cell culture and in vivo mouse models of hepatocellular carcinoma with IDN-7314, an orally active pan-caspase inhibitor, is being presented at The ...
04/18/16 05:40 PMAnalysts Offer Insights on Healthcare Companies: Conatus Pharmaceuticals (NASDAQ: CNAT), 22nd Century Group ... - Analyst Ratings - Analysts Offer Insights on Healthcare Companies: Conatus Pharmaceuticals (NASDAQ: CNAT), 22nd Century Group ...Analyst RatingsIn a report issued on April 15, Vernon Bernardino from FBR Capital reiterated a Buy rating on Conatus Pharmaceuticals (NASDAQ: CNAT). The company's shares closed last Friday at $3.05. Conatus Pharmaceuticals has an analyst consensus of Moderate ...
About Conatus Pharmaceuticals

Conatus Pharmaceuticals logoConatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CNAT
  • CUSIP:
Key Metrics:
  • Previous Close: $2.16
  • 50 Day Moving Average: $2.16
  • 200 Day Moving Average: $2.26
  • P/E Ratio: N/A
  • P/E Growth: -0.04
  • Market Cap: $45.52M
  • Current Quarter EPS Consensus Estimate: $-1.56 EPS
Additional Links:
Conatus Pharmaceuticals (NASDAQ:CNAT) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha